Novartis India Limited
NSE: NOVARTIND BSE: NOVARTIND
NSE
674.00
1.75 (0.26%)
Prev Close
672.25
Open Price
691.05
Volume
11,669
Today Low / High
672 / 698.2
52 WK Low / High
537 / 909
Range
640 - 708
BSE
914.05
-6.20 (-0.67%)
Prev Close
920.25
Open Price
925
Volume
2,763
Today Low / High
902.5 / 934.05
52 WK Low / High
744.95 / 1248
Range
868 - 960
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 674 (target range: 640 - 708), reflecting a change of 1.75 (0.2603%). On the BSE, it is listed at 914.05 (target range: 868 - 960), showing a change of -6.2 (-0.67373%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
Novartis India Limited Graph
Novartis India Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Novartis India Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 674.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 914.05 | 923.19 | 830.87 - 1,015.51 |
| 932.33 | 745.86 - 1,118.80 | ||
| 941.47 | 659.03 - 1,223.91 | ||
| Bearish Scenario | 914.05 | 904.91 | 814.42 - 995.40 |
| 895.77 | 716.62 - 1,074.92 | ||
| 886.63 | 620.64 - 1,152.62 |
Overview of Novartis India Limited
ISIN
INE234A01025
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
5,696
Market Cap
17,477,088,926
Last Dividend
25
Official Website
IPO Date
2020-10-07
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of NOVARTIND
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-07-23 | July 23, 24 | 25 | 25 | 2024-07-23 | 2024-08-30 | |
| 2023-07-20 | July 20, 23 | 37.5 | 37.5 | 2023-07-20 | 2023-08-27 | |
| 2022-07-20 | July 20, 22 | 10 | 10 | 2022-07-21 | 2022-08-28 | |
| 2021-08-17 | August 17, 21 | 10 | 10 | 2021-08-19 | 2021-09-26 | |
| 2020-07-29 | July 29, 20 | 10 | 10 | 2020-07-30 | 2020-09-06 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 356.27 Cr | 202.82 Cr | 153.45 Cr | 0.4307 | 0.00 Cr | 4.16 Cr | 134.90 Cr | 100.90 Cr | 40.87 | 96.82 Cr | 0.2832 |
| 2024-03-31 | 335.07 Cr | 202.38 Cr | 132.69 Cr | 0.3960 | 0.00 Cr | 6.78 Cr | 65.26 Cr | 85.19 Cr | 34.50 | 126.93 Cr | 0.2542 |
| 2023-03-31 | 369.11 Cr | 204.62 Cr | 164.49 Cr | 0.4456 | 0.00 Cr | 6.42 Cr | 67.66 Cr | 103.36 Cr | 41.86 | 123.19 Cr | 0.2800 |
| 2022-03-31 | 387.57 Cr | 181.48 Cr | 206.09 Cr | 0.5317 | 0.00 Cr | 7.95 Cr | 18.38 Cr | -3.72 Cr | -1.51 | 10.66 Cr | -0.0096 |
| 2021-03-31 | 365.61 Cr | 149.63 Cr | 215.98 Cr | 0.5907 | 0.00 Cr | 6.41 Cr | 16.66 Cr | 20.90 Cr | 8.46 | 59.88 Cr | 0.0572 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 648.03 Cr | 947.81 Cr | 162.85 Cr | 784.9600 Cr | 5.06 Cr | -642.97 Cr | 41.11 Cr | 4.54 Cr | 0.00 Cr | 0.00 Cr | 1.06 Cr | 142.0500 Cr |
| 2024-03-31 | 44.98 Cr | 924.93 Cr | 180.11 Cr | 744.8200 Cr | 6.97 Cr | -38.01 Cr | 44.86 Cr | 6.94 Cr | 2.31 Cr | 0.00 Cr | -537.83 Cr | 157.2000 Cr |
| 2023-03-31 | 19.42 Cr | 982.94 Cr | 207.28 Cr | 775.6600 Cr | 21.51 Cr | 2.09 Cr | 54.72 Cr | 19.25 Cr | 1.87 Cr | 0.00 Cr | 0.86 Cr | 159.4900 Cr |
| 2022-03-31 | 158.35 Cr | 957.57 Cr | 265.87 Cr | 691.7000 Cr | 24.01 Cr | -134.34 Cr | 57.07 Cr | 23.65 Cr | 1.36 Cr | 0.00 Cr | 1.40 Cr | 216.4200 Cr |
| 2021-03-31 | 68.27 Cr | 1,002.29 Cr | 291.10 Cr | 711.1900 Cr | 62.48 Cr | -5.79 Cr | 47.95 Cr | 63.91 Cr | 1.50 Cr | 0.00 Cr | 1.16 Cr | 158.9500 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 74.5700 Cr | -3.3100 Cr | -64.1500 Cr | 74.5700 Cr | 7.1100 Cr | 52.0700 Cr | 0.0000 Cr | 100.9000 Cr | -2.4100 Cr | -61.7300 Cr | 3.7500 Cr |
| 2024-03-31 | 113.4000 Cr | 33.1300 Cr | -120.9900 Cr | 113.4000 Cr | 25.5400 Cr | 44.9600 Cr | 0.0000 Cr | 85.1900 Cr | 0.0000 Cr | -117.2800 Cr | 9.8600 Cr |
| 2023-03-31 | 44.8000 Cr | -153.2500 Cr | -30.4800 Cr | 44.4900 Cr | -138.9300 Cr | 19.4200 Cr | -0.3100 Cr | 115.3800 Cr | 0.0000 Cr | -24.6900 Cr | 2.3500 Cr |
| 2022-03-31 | 38.6700 Cr | 87.0400 Cr | -35.6300 Cr | 38.1700 Cr | 90.0800 Cr | 158.3500 Cr | -0.5000 Cr | -3.8200 Cr | 0.0000 Cr | -24.6900 Cr | -9.1200 Cr |
| 2021-03-31 | -69.2100 Cr | 95.1600 Cr | -36.8000 Cr | -69.3000 Cr | -10.8500 Cr | 68.2700 Cr | -0.0900 Cr | 40.0400 Cr | 0.0000 Cr | -24.6900 Cr | 10.7300 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 87.55 Cr | 46.77 Cr | 40.78 Cr | 0.4658 | 26.68 Cr | 27.62 Cr | 11.19 | 37.85 Cr | 0.3155 |
| 2025-03-31 | 83.88 Cr | 49.30 Cr | 34.58 Cr | 0.4123 | 31.61 Cr | 29.30 Cr | 11.87 | 29.33 Cr | 0.3493 |
| 2024-12-31 | 93.00 Cr | 50.46 Cr | 42.54 Cr | 0.4574 | 25.09 Cr | 25.45 Cr | 10.31 | 36.18 Cr | 0.2737 |
| 2024-09-30 | 87.10 Cr | 54.93 Cr | 32.17 Cr | 0.3693 | 17.38 Cr | 20.40 Cr | 8.27 | 28.27 Cr | 0.2342 |
| 2024-06-30 | 92.29 Cr | 53.91 Cr | 38.38 Cr | 0.4159 | 23.42 Cr | 25.74 Cr | 10.42 | 34.38 Cr | 0.2789 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 648.03 Cr | 0.00 Cr | 648.03 Cr | 40.14 Cr | 41.11 Cr | 745.82 Cr | 4.54 Cr | 947.81 Cr | 162.85 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 597.24 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -729.24 Cr |
| 2024-09-30 | 597.24 Cr | 576.61 Cr | 597.24 Cr | 38.11 Cr | 33.58 Cr | 695.32 Cr | 5.63 Cr | 890.91 Cr | 161.67 Cr |
| 2024-06-30 | -584.98 Cr | 1,169.96 Cr | 584.98 Cr | 0.00 Cr | 0.00 Cr | 584.98 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 596.08 Cr | 551.91 Cr | 596.08 Cr | 51.24 Cr | 44.86 Cr | 699.26 Cr | 6.94 Cr | 924.93 Cr | 180.11 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 29.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 25.45 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 20.41 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 25.74 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 14.68 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,641.80 | ₹3,939,137,904,000.00 | ₹2,098,280.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,151.50 | ₹1,633,032,553,500.00 | ₹681,521.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,685.30 | ₹1,247,271,358,500.00 | ₹279,863.00 |
| Mankind Pharma Limited | MANKIND | ₹2,606.80 | ₹1,075,901,331,568.00 | ₹731,305.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,277.60 | ₹1,063,387,459,020.00 | ₹1,229,762.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹988.80 | ₹994,960,224,000.00 | ₹307,413.00 |
| Lupin Limited | LUPIN | ₹1,974.70 | ₹901,938,300,900.00 | ₹380,522.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,426.00 | ₹648,759,690,000.00 | ₹99,581.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,050.40 | ₹610,074,420,800.00 | ₹1,872,840.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,937.30 | ₹546,707,997,300.00 | ₹466,930.00 |
| Laurus Labs Limited | LAURUSLABS | ₹879.10 | ₹474,560,157,500.00 | ₹1,548,001.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,418.40 | ₹359,853,753,600.00 | ₹437,395.00 |
| Cohance Lifesciences Limited | COHANCE | ₹884.70 | ₹338,457,031,978.00 | ₹105,334.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,638.50 | ₹329,643,636,000.00 | ₹49,045.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,747.90 | ₹273,268,433,900.00 | ₹250,994.00 |
| Piramal Enterprises Limited | PEL | ₹1,167.70 | ₹264,691,900,600.00 | ₹183,898.00 |
| Eris Lifesciences Limited | ERIS | ₹1,768.70 | ₹240,909,320,900.00 | ₹37,828.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,479.40 | ₹240,371,432,600.00 | ₹246,819.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,433.00 | ₹210,825,000,000.00 | ₹11,150.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹974.60 | ₹191,570,299,800.00 | ₹29,498.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,888.00 | ₹178,181,651,200.00 | ₹28,474.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,083.00 | ₹172,501,323,000.00 | ₹140,398.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,168.10 | ₹164,800,966,770.00 | ₹172,510.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹882.45 | ₹158,055,619,500.00 | ₹259,072.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹458.50 | ₹111,252,274,000.00 | ₹945,550.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,581.50 | ₹109,248,951,100.00 | ₹46,177.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹851.90 | ₹83,308,067,710.00 | ₹36,218.00 |
| Strides Pharma Science Limited | STAR | ₹865.50 | ₹79,775,471,850.00 | ₹92,326.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹863.25 | ₹78,240,335,715.00 | ₹294,141.00 |
| FDC Limited | FDC | ₹474.65 | ₹77,277,766,500.00 | ₹198,253.00 |
| Innova Captab Limited | INNOVACAP | ₹911.35 | ₹52,151,939,956.00 | ₹70,484.00 |
| Suven Life Sciences Limited | SUVEN | ₹230.75 | ₹50,320,575,500.00 | ₹56,095.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹146.08 | ₹47,406,173,760.00 | ₹195,028.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹483.05 | ₹44,087,973,500.00 | ₹160,106.00 |
| Sequent Scientific Limited | SEQUENT | ₹175.85 | ₹44,021,409,750.00 | ₹240,104.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹772.20 | ₹39,165,289,020.00 | ₹31,316.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,358.20 | ₹39,002,269,800.00 | ₹5,512.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹363.25 | ₹36,425,983,500.00 | ₹39,528.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹502.80 | ₹35,400,036,240.00 | ₹9,585.00 |
| Hikal Limited | HIKAL | ₹254.90 | ₹31,429,424,900.00 | ₹3,140,867.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹631.60 | ₹30,413,434,800.00 | ₹53,855.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹96.82 | ₹28,419,284,140.00 | ₹848,541.00 |
| Alembic Limited | ALEMBICLTD | ₹105.52 | ₹27,095,636,534.00 | ₹249,022.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹49.03 | ₹26,866,184,620.00 | ₹2,369,065.00 |
| Indoco Remedies Limited | INDOCO | ₹279.55 | ₹25,787,900,445.00 | ₹12,570.00 |
Key Executives
Chief Executive Officer of Novartis
Dr. Vasant Narasimhan M.D.
Gender: Not Specified
Year Born: 1976
Chief Financial Officer & Whole-Time Director
Ms. Shilpa Shashank Joshi
Gender: female
Year Born: 1969
Company Secretary & Compliance Officer
Ms. Chandni Maru
Gender: female
Year Born:
WholeTime Director
Mr. Falin Ishwarlal Majmudar
Gender: male
Year Born: 1968
FAQs about Novartis India Limited
Who is the CEO of the company?
The CEO is Vasant Narasimhan.
What is the current market price of the stock?
The current price is ₹674.00.
What is the 52-week price range?
The range is ₹537.0-909.0.
What is the market capitalization of the company?
The market capitalization is ₹1,747.71 crores.
What is the dividend yield?
The dividend yield is 2.74%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 21.95.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Novartis India Limited (ISIN: INE234A01025) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹1,747.71 crores and an average daily volume of 5,696 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹25.